Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21393205 | 0.83 | AURKA (0.32) | HSD11B1 | |
| SCHEMBL18022517 | 0.72 | CYP2A6 (0.48) | CYP19A1 | |
| SCHEMBL13328613 | 0.72 | CYP2A6 (0.48) | CYP19A1 | |
| SCHEMBL12251108 | 0.72 | CYP2A6 (0.48) | CYP19A1 | |
| SCHEMBL21122380 | 0.69 | TRPV3 (0.32) | — | |
| SCHEMBL23006785 | 0.69 | IRAK4 (0.38) | — | |
| SCHEMBL10229765 | 0.69 | CYP2A6 (0.47) | CYP19A1 | |
| SCHEMBL13557870 | 0.68 | CYP2A6 (0.52) | CYP19A1 | |
| SCHEMBL19085083 | 0.66 | CCR1 (0.39) | — | |
| SCHEMBL30509594 | 0.65 | TSHR (0.54) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | HSD11B1 2679/4885ALOX5AP 3561/4885CYP19A1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.